Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Lower By -5.84% This Week? InvestorsObserver
Zero emission vehicles: first Fit for 55 deal will end the sale of new CO2 emitting cars in Europ... Modern Diplomacy
Excerpt from:
Zero emission vehicles: first Fit for 55 deal will end the sale of new CO2 emitting cars in Europ... - Modern Diplomacy
DUBLIN--(BUSINESS WIRE)--The "Biotechnology Market Research Report by Technology (Cell-based Assays, Chromatography, and DNA Sequencing), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Biotechnology Market size was estimated at USD 876.74 billion in 2021, USD 1,023.15 billion in 2022, and is projected to grow at a CAGR 16.87% to reach USD 2,234.84 billion by 2027.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biotechnology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biotechnology Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biotechnology Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biotechnology Market?
4. What is the competitive strategic window for opportunities in the Global Biotechnology Market?
5. What are the technology trends and regulatory frameworks in the Global Biotechnology Market?
6. What is the market share of the leading vendors in the Global Biotechnology Market?
7. What modes and strategic moves are considered suitable for entering the Global Biotechnology Market?
Market Dynamics
Drivers
Restraints
Opportunities
Challenges
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/ijpdlj
Read the rest here:
The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 - ResearchAndMarkets.com - Business Wire
In brief
By National Law No. 27,685 ("Law"), published on 16 September 2022, Law No. 26,270 was amended, expanding throughout the entire national territory the promotion regime for the development and production of modern biotechnology and nanotechnology. The regime will be in force up to 31 December 2034.
The Law set forth the following tax benefits: (i) the accelerated amortization of the capital goods, special equipment, and parts or elements forming those new goods, which were acquired for the project; (ii) the anticipated refund for the VAT corresponding to the goods acquired for the project; and (iii) the granting of a tax credit bond equivalent to 50% of expenses paid for hiring investigative and development services from institutions that are part of the national public system of science, technology and innovation. The tax credit bond will be valid for 10 years and it will only be transferable once.
In focus
The Law includes the concept of nanotechnology in the definition of "Modern Biotechnology", which means every technological application based on rational knowledge and scientific principles that derive from biology, biochemistry, microbiology, bioinformatics, molecular biology and genetic engineering, or that uses live organisms or parts of them, either for the production of goods and services, or for the substantial improvement of products and productive processes.
The Law set forth the following tax benefits:
Click here to download the Spanish version.
Content is provided for educational and informational purposes only and is not intended and should not be construed as legal advice. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee similar outcomes. For more information, please visit:www.bakermckenzie.com/en/client-resource-disclaimer.
Read more from the original source:
Argentina: Promotion of modern biotechnology and nanotechnology - Lexology
Press release
Cambridge, MA U.S.A. (September 26, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022.
Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director.
I am delighted that Jerry has chosen to join Allaritys board at this crucial time in our evolution, said Dr. Duncan Moore, Allaritys Chairman of the Board. His operational experience in clinical stage therapeutic development and capital markets acumen will be of great value as we continue to implement the Companys combination therapy-focused strategy.
Mr. McLaughlin said: I firmly believe Allarity Therapeutics is in a unique position to become a leader within the personalized medicine space by developing novel combination oncology therapies together with the Companys unique DRP companion diagnostics. Allaritys recent strategic shift is aligned with the ongoing patient and market realities in oncology, as we continue to see substantially higher patient benefits with combination therapies. I look forward to supporting the CEO, Jim Cullem, and the rest of the Allarity team in unlocking both the clinical and commercial potential of this strategy.
Mr. McLaughlin has three decades of experience in leading operational and executive management roles. He made key contributions to significant life science milestones, including product launches, acquisitions, and financings. He is currently serving as CEO and Board Member of Life Biosciences, LLC, a development-stage biopharmaceutical company advancing therapeutics for patients with neurological and psychiatric diseases. Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.) Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc. Earlier in his career, he held corporate leadership roles at NuPathe, Inc., Endo Pharmaceuticals Inc., and Merck & Co., Inc. He received his B.A. from Dickinson College and his MBA from Villanova University in Pennsylvania.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and the European rights to IXEMPRA (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis, a liposomal formulation of cisplatin and its accompanying DRP, being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Companys website at http://www.Allarity.com.
About the Drug Response Predictor DRP Companion Diagnostic
Allarity uses its drug-specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA. The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.
Follow Allarity on Social Media
Facebook: https://www.facebook.com/AllarityTx/ LinkedIn: https://www.linkedin.com/company/allaritytx/ Twitter: https://twitter.com/allaritytx
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allaritys current expectations or forecasts of future events. The words anticipates, believe, continue, could, estimate, expect, intends, may, might, plan, possible, potential, predicts, project, should, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to clinical and commercial potential due to the Company advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Companys DRP companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to,the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Companys current and future clinical trials and the timing of the Companys preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our Form S-1 registration statementon file with theSecurities and Exchange Commission, available at the Securities and Exchange Commissions website atwww.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Companys subsequent filings with theSecurities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
Thomas JensenSenior V.P. of Investor Relationsinvestorrelations@allarity.com
Investor Relations:
Chuck PadalaLifeSci Advisors+1(646) 627-8390chuck@lifesciadvisors.comU.S. Media Contact:
Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com
EU Media Contact:
Thomas PedersenCarrotize PR & Communications +45 6062 9390tsp@carrotize.com
Read the original post:
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors - GlobeNewswire
As a rapidly advancing climate emergency turns the planet ever hotter, the Dallas-based biotechnology company Colossal Biosciences has a vision: To see the Woolly Mammoth thunder upon the tundra once again. Founders George Church and Ben Lamm have already racked up an impressive list of high-profile funders and investors, including Peter Thiel, Tony Robbins, Paris Hilton, Winklevoss Capital and, according to the public portfolio its venture capital arm released this month, the CIA.
Colossal says it hopes to use advanced genetic sequencing to resurrect two extinct mammals not just the giant, ice age mammoth, but also a mid-sized marsupial known as the thylacine, or Tasmanian tiger, that died out less than a century ago. On its website, the company vows: Combining the science of genetics with the business of discovery, we endeavor to jumpstart natures ancestral heartbeat.
In-Q-Tel, its new investor, is registered as a nonprofit venture capital firm funded by the CIA. On its surface, the group funds technology startups with the potential to safeguard national security. In addition to its long-standing pursuit of intelligence and weapons technologies, the CIA outfit has lately displayed an increased interest in biotechnology and particularly DNA sequencing.
Why the interest in a company like Colossal, which was founded with a mission to de-extinct the wooly mammoth and other species? reads an In-Q-Tel blog post published on September 22. Strategically, its less about the mammoths and more about the capability.
Biotechnology and the broader bioeconomy are critical for humanity to further develop. It is important for all facets of our government to develop them and have an understanding of what is possible, Colossal co-founder Ben Lammwrote in an email to The Intercept. (A spokesperson for Lamm stressed that while Thiel provided Church with$100,000 in funding to launchthe woolly mammoth project that became Colossal, he is not a stakeholderlike Robbins, Hilton, Winklevoss Capital, and In-Q-Tel.)
Colossal uses CRISPR gene editing, a method of genetic engineering based on a naturally occurring type of DNA sequence. CRISPR sequences present on their own in some bacterial cells and act as an immune defense system, allowing the cellto detect and excise viral material thattries to invade. The eponymous gene editing technique was developed to function the same way, allowing users to snip unwanted genes and program a more ideal version of the genetic code.
CRISPR is the use of genetic scissors, Robert Klitzman, a bioethicist at Columbia University and a prominent voice of caution on genetic engineering, told The Intercept. Youre going into DNA, which is a 3-billion-molecule-long chain, and clipping some of it out and replacing it. You can clip out bad mutations and put in good genes, but these editing scissors can also take out too much.
The embrace of this technology, according to In-Q-Tels blog post, will help allow U.S. government agencies to read, write, and edit genetic material, and, importantly, tosteerglobal biological phenomena that impact nation-to-nation competition whileenabling the United States to help set the ethical, as well as the technological, standards for its use.
In-Q-Tel did not respond to The Intercepts requests for comment.
In recent years, the venture firms portfolio has expanded to include Ginkgo Bioworks, a bioengineering startup focused on manufacturing bacteria for biofuel and other industrial uses; Claremont BioSolutions, a firm that produces DNA sequencing hardware; Biomatrica and T2 Biosystems, two manufacturers for DNA testing components; and Metabiota, an infectious disease mapping and risk analysis database powered by artificial intelligence. As The Intercept reported in 2016, In-Q-Tel also invested in Clearista, a skincare brand that removes a thin outer epidermal layer to reveal a fresher face beneath it and allow DNA collection from the skin cells scraped off.
President Joe Bidens administration signaled its prioritization of related advances earlier this month, when Biden signed an executive order on biotechnology and biomanufacturing. The order includes directives to spur public-private collaboration, bolster biological risk management, expand bioenergy-based products, and engage the international community to enhance biotechnology R&D cooperation in a way that is consistent with United States principles and values.
The governments penchant for controversial biotechnology long predates the Biden administration. In 2001, a New York Times investigation found that American defense agencies under Presidents George W. Bush and Bill Clinton had continued to experiment with biological weapons, despite a 1972 international treaty prohibiting them. In 2011, The Guardian revealed that the CIA under President Barack Obama organized a fake Hepatitis B vaccine drive in Pakistan that sought to locate family members of Osama bin Laden through nonconsensual DNA collection, leading the agency to eventually promise a cessation of falseimmunization campaigns.
CIA Labs, a 2020 initiative overseen by Donald Trumps CIA director, Gina Haspel infamous for running a torture laboratory in Thailand follows a model similar to In-Q-Tels. The program created a research network to incubate top talent and technology for use across U.S. defense agencies, while simultaneously allowing participating CIA officers to personally profit off their research and patents.
In-Q-Tel board members are allowed to sit on the boards of companies in which the firm invests, raising ethics concerns over howthe non-profit selects companies to back with government dollars. A 2016 Wall Street Journal investigation found that almost half of In-Q-Tel board members were connected to the companies where it had invested.
The size of In-Q-Tels stake in Colossal wont be known until the nonprofit releases its financial statements next year, but the investment may provide a boon on reputation alone: In-Q-Tel has claimed that every dollar it invests in a business attracts 15 more from other investors.
Colossals co-founders, Lamm and Church, represent the ventures business and science minds, respectively. Lamm, a self-proclaimed serial technology entrepreneur, founded his first company as a senior in college, then pivoted to mobile apps and artificial intelligence before helping to start Colossal.
Church a Harvard geneticist, genome-based dating app visionary, and former Jeffrey Epstein funding recipient has proposed the revival of extinct species before. Speaking to Der Spiegel in 2013, Church suggested the resurrection of the Neanderthal an idea met with controversy because it would require technology capable of human cloning.
We can clone all kinds of mammals, so its very likely that we could clone a human, Church said. Why shouldnt we be able to do so? When the interviewer reminded him of a ban on human cloning, Church said, And laws can change, by the way.
Even when the methods used for de-extinction are legal, many scientists are skeptical of its promise. In a 2017 paper for Nature Ecology & Evolution, a group of biologists from Canada, Australia, and New Zealand found that [s]pending limited resources on de-extinction could lead to net biodiversity loss.
De-extinction is a fairytale science, Jeremy Austin, a University of Adelaide professor and director of the Australian Center for Ancient DNA,toldthe Sydney Morning Herald over the summer, when Colossal pledged to sink $10 million into the University of Melbourne for its Tasmanian tiger project. Its pretty clear to people like me that thylacine or mammoth de-extinction is more about media attention for the scientists and less about doing serious science.
Critics who say de-extinction of genes to create proxy species is impossible are critics who are simply not fully informed and do not know the science. We have been clear from day one that on the path to de-extinction we will be developing technologies which we hope to be beneficial to both human healthcare as well as conservation, Lamm wrote to The Intercept. We will conitnue [sic] to share these technologies we develop with the world.
It remains to be seen if Colossal, with In-Q-Tels backing, can make good on its promises. And its unclear what, exactly, the intelligence world might gain from the use of CRISPR. But perhaps the CIA shares the companys altruistic, if vague, motives: To advance the economies of biology and healing through genetics. To make humanity more human. And to reawaken the lost wilds of Earth. So we, and our planet, can breathe easier.
Update: September 28, 2022, 1:00 p.m. ETThis story has been updated with a statement from Colossal co-founder Ben Lamm.
View post:
CIA Just Invested In Woolly Mammoth Resurrection Tech - The Intercept
Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis
Novel combination strategy designed toreduce HDV viremia and block viral entry
SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.
VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that diminishes the level of all HBV proteins in vitro, including hepatitis B surface antigen, a protein necessary to create infectious HDV virions. VIR-3434 is an investigational hepatitis B surface antigen targeting monoclonal antibody designed to remove both HBV and HDV virions from the blood and block the entry of these viruses into liver cells. VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial. Previously reported results from Part A of the MARCH trial demonstrated that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline in hepatitis B surface antigen (HBsAg).
Globally, more than 12 million people are living with HDV, and with no approved therapies available in the United States, there is an urgent need for the development of novel treatment strategies that will improve outcomes for patients, said Carey Hwang, M.D., Ph.D., Virs senior vice president, clinical research, head of chronic infection. Recent research suggests that reducing HDV viremia, by preventing virion formation as well as facilitating virion removal, in conjunction with blocking HDV virion entry into liver cells could be effective in suppressing chronic HDV infection. The initiation of SOLSTICE, our first clinical trial in HDV, is an important milestone as we advance our broad therapeutic portfolio for viral hepatitis, which also includes the pursuit of a functional cure for chronic HBV infection.
Design of the Phase 2 SOLSTICE TrialThe multi-center, open-label Phase 2 SOLSTICE trial is designed to evaluate the safety, tolerability, and efficacy of VIR-2218 and VIR-3434 in adult patients (age 18 to 69) with chronic HDV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Depending on the cohort, trial participants will receive multiple doses of VIR-2218 and VIR-3434 as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks. The primary endpoints of the trial are the proportion of study participants achieving either a 2log10 decrease in HDV RNA compared to baseline, or HDV RNA less than the limit of quantification and normalization of alanine transaminase (ALT) at Week 24, as well as the proportion of participants with treatment-emergent adverse events and serious adverse events. Vir expects initial data from the SOLSTICE trial in 2023.
About Chronic Hepatitis DChronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV). An estimated 12 million patients globally are infected with HDV, representing approximately 5% of those infected with HBV. HDV-HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression toward hepatocellular carcinoma and liver-related death.
About Chronic Hepatitis BChronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality. Approximately 300 million people around the world are living with HBV and approximately 900,000 of them die from associated complications each year. These patients are significantly underserved by existing therapies with low functional cure rates, lifelong daily therapy and poor tolerability. Vir is working to achieve a functional cure for the millions of people with HBV around the world through its broad and differentiated portfolio.
About VIR-2218VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About VIR-3434VIR-3434 is an investigational subcutaneously administered antibody designed to block entry of HBV and HDV viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencors Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV and HDV in infected patients, as well as to have an extended half-life.
About Vir BiotechnologyVir Biotechnologyis a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, expect, anticipate, promising and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of VIR-2218 and VIR-3434 in combination to treat chronic HDV and HBV infection; the potential benefits of VIR-2218 and VIR-3434; Virs plans and expectations for its HDV and HBV portfolios; the initial results of the MARCH trial; the timing for and design of the Phase 2 SOLSTICE trial; the treatment of HDV and HBV; and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including risks that Vir may not fully enroll the Phase 2 SOLSTICE trial or it will take longer than expected; unexpected safety or efficacy data or results observed during the Phase 2 SOLSTICE trial or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; successful development and/or commercialization of alternative product candidates by Virs competitors; changes in expected or existing competition; delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Go here to see the original:
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis...
England is in crisis. They lost a beloved figurehead this month but for decades prior were losing scientific ground. If you look for the home of the modern organic food and anti-vaccine movements, you find their nexus in 1990s England.
The primary royal behind those beliefs is now King Charles III.
In order to manage the $28 billion he inherits (tax-free, paying taxes only applies to peasants in England)(1) he will have to give his $1.5 billion estate to his son, the new Prince of Wales, William (also tax free) but the Prince is not only taking over during a time when Brits are wondering why they still care about a throne that hasnt been relevant in hundreds of years, he is taking over at a time when being anti-science is no longer fashionable for progressive elites.
Though it was recently the darling of the intelligentsia, and Prince Charles longed to belong in that circle, anti-vaccine sentiments have become proletariat since COVID-19. The war on science when it comes to food harms a lot more people worldwide each year than the pandemic did. Hundreds of thousands of kids could stop going blind each year with Golden Rice but elites like King Charles III give money to groups that block its implementation.
Prince William could start to gain back some credibility for the family by jettisoning the organic food fetish of his father. Organic food, like the anti-vaccine movement, is a relic of 1990s England. Dr. Andrew Wakefield set off the modern anti-vaccine craze the same way that English environmental activists set off the Frankenfood one. Now supplements, wellness, and organic are all giant businesses based on exploitation of famous names who wanted to impress their elite friends
The world should have passed the anti-vaccine and anti-food movement by but they persist in large part because of the new British monarch and his quasi-American royalty of American Democrats counterpart, Robert F. Kennedy, Jr.(2)
Its easy to embrace science, especially in light of their history making changes when it was needed. They changed their name to Windsor from Saxe-Coburg and Gotha during World War I to help commoners forget the British royal family is German during a time that Germany was shooting at English men in Europe. Given that public relations success, they can certainly change their tune when it comes to science.
Perhaps due to an infusion of new blood outside the shockingly limited pool drawn from during the 19th and 20th centuries, Prince William seems to be a more genetically gifted thinker than his father. He can show it by embracing the modern world, where food and medicine are embraced.(3)
He doesnt actually have to divest from the farm, that is just me getting attention in a title. It is enough if he acknowledges that having peasants toil for his carrots only using specially labeled toxic pesticides is a pastime for the rich, and not a way to feed the world.
(1) The same way California Governor Gavin Newsom doesnt want people who make over $2 million each year to pay higher taxes to subsidize the electric cars the Governor insists Uber drivers need to buy. High taxes are for the middle class and the poor, not the donors he will need in order to fail running for President in 2024.
(2) Nothing looks more hypocritical than people on the left in England and the US suddenly endorsing vaccines when just two years ago they opposed them. It instead reeks of politics, and politics need to be a no-no for the new generation of British royals, lest they be relegated to the name recognition of the Queen of the Netherlands, whoever that is.
(3) and not just engage in publicity stunts about energy costs that are squarely the blame of the government his father now seeks to lead.
Hank Campbell founded Science 2.0 in 2006, and writes for USA Today, Wall Street Journal, CNN, and more. His first book,Science Left Behind,was the #1 bestseller on Amazon for environmental policy books. Follow Hank on Twitter@HankCampbell
A version of this article was originally posted atScience 2.0and is reposted here with permission. Science 2.0 can be found on Twitter@science2_0
See the original post here:
Viewpoint: Will King Charles abandon his kooky ideas about agriculture and help accelerate Britain's embrace of sustainable biotechnology tools? -...
Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. So if youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors.
Aurinia is a pharmaceutical company focused on developing therapies for patients with rare and neglected diseases. The companys lead product, voclosporin, is designed to treat lupus nephritis, a kidney inflammation caused by systemic lupus erythematosus (lupus). The company has a robust business model, and voclosporin effectively treats lupus nephritis in several clinical trials. Aurinia is expected to begin Phase III clinical trials for voclosporin in early 2022. Aurinia Pharmaceuticals is currently trading at $4.56 per share. The company has a market cap of $1.03 billion and a price-to-book ratio of 1.44. The company is expected to have annual revenue of $784 million in 2022.
Verve is a pharmaceutical company focused on developing therapies for rare central nervous system (CNS) disorders and diseases of the eye. The companys lead product, a treatment for retinal vein occlusion (RVO), is currently in Phase III clinical trials. Verve was formed due to a merger between Neurocrine Biosciences and Ferrokinetics. After the two companies merged, the company was renamed Verve Therapeutics and continued to work on the same RVO treatment. Verves RVO treatment is expected to be commercially available in 2022. Verve Therapeutics is currently trading at $3.63 per share. The company has a market cap of $1.32 billion and a price-to-book ratio of 0.99. The company is expected to have annual revenue of $539 million in 2022.
Neurocrine is a biopharmaceutical company focused on developing therapies for severe and rare diseases. The companys lead product, INGREZZA, is destructive dyskinesia (TD), a movement disorder characterized by involute notary facial, arm, and leg movements. TD is a severe and long-term condition that is often associated with the use of certain psychiatric medications. INGREZZA is effective in treating TD in several clinical trials. Neurocrine was formed due to a merger between Vercure Pharmaceuticals and Ferrokinetics. After the two companies merged, the company was renamed Neurocrine Biosciences. Neurocrine Biosciences is currently trading at $26.37 per share. The company has a market cap of $5.37 billion and a price-to-book ratio of 1.69. The company is expected to have annual revenue of $1.13 billion in 2022.
Regenxbio is a biopharmaceutical company focused on developing immuno-oncology therapies and bispecific antibodies (Bi-SBIs). Immuno-oncology treatments are being developed to treat various cancers by activating the immune system. Bi-SBIs are engineered to bind to two different targets at the same time. The companys lead product, RG101, is being developed as a treatment for diabetic macular edema (DME), a degenerative eye disease that affects individuals with diabetes. RG101 is effective in treating DME in several clinical trials. In addition, the U.S. Food and Drug Administration (FDA) has also granted Breakthrough Therapy Designation designation. Regenxbio is currently trading at $27.09 per share. The company has a market cap of $2.39 billion and a price-to-book ratio of 4.24. The company is expected to have annual revenue of $1.32 billion in 2022.
Biotechnology is a fast-growing field that is revolutionizing healthcare and other industries. Biotech companies are developing new drugs, diagnostics, and agricultural products to meet the needs of society and global markets. Biotech stocks have also been performing well as of late. The market has been kind to biotech stocks over the past couple of years, and many analysts suggest that this trend will continue into 2022. If youre looking for some great biotech stocks to buy in 2022, we can help you out. This article will discuss three top biotech stocks to buy in 2022 and provide helpful information about these companies and their competitors. Now its time for you to decide which biotech stocks to buy in 2022. Remember that these are just some suggestions, so do your research before investing in any company or store.
Go here to see the original:
Top Biotechnology Stocks to Buy in 2022 - Best Stocks
There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and quality of life.
People often bequest money in their will to these organisations, donate after a loved one has been struck down by a particular illness or at funerals ask for donations to a an organisation in lieu of traditional flowers.
And while these organisations do great work, what about considering investing directly in medical companies for the greater good? Biotechnology investing is one sector which stands out for not only potential to deliver quality returns but also contribute positively to society.
Australias biotech representative body AusBiotech CEO Lorraine Chiroiu told Stockhead many of us unfortunately have a personal connection to catastrophic disease and, motivated by our experiences, are seeking avenues to put our philanthropic and investment dollars where we can make a meaningful and sustainable difference.
AusBiotech is receiving increasing enquiries from people who want to gift, bequeath or invest in a way that gives the best chance of new medical treatments and cures making their way to people experiencing disease, she said.
For example, we recently received a call from a father whose only son had passed away from cancer. Nobly, he wanted to make a purposeful investment into a company working to provide treatment for the disease that took his son in the hope that other families wouldnt have to go through the same suffering as his family.
Indeed many biotech companies have been founded by grieving family or friends that are passionate about finding a cure for a disease that took their loved one too soon.
Chiroiu said biotechnology companies are the vehicles that move medical research along the translation and commercialisation pathway to patients.
Companies operating in the life science and medtech sectors are in a unique position where business foundations are often influenced by a strong value-driven purpose one that offers positive social impact as the company develops life-saving and life-enhancing technologies.
Focusing clearly on patient impact, social good is codified into biotech companies DNA and are a great avenue for ethical investors to consider diversifying their portfolio.
She said we are living in an age of profound acceleration in medicinal discoveries and healthcare options, as well as a time that the Covid-19 pandemic has brought biotechnology especially in the form of vaccines into sharp focus.
As we emerge from the pandemic, the chronic health challenges and increasing burdens of disease associated with ageing populations around the world has many of us wondering how we can help move medical research from the bench to the bedside the answer is via business, she said
Australias biotech industry is on a strong growth trajectory, through substantially increasing numbers of organisations. Figures released by AusBiotech show the sector has grown 43% since 2019 and 60% since 2017.
Amid a thriving and expanding biotech industry in Australia, feeding the need for commercialisation, clinical development and growth is key and the diversity of investment sources remains a pressing issue, Chiroiu said.
Capital is the lifeblood of these companies and in response to this increasing need, AusBiotech has bolstered its investment program with a goal that Australian and overseas investors increasingly see Australian life sciences research and small-to-medium enterprises as viable and attractive investment options.
Global X head of investment strategy Blair Hannon told Stockhead biotechnology investing is well positioned to tick the boxes of environmental, social and governance (ESG) considerations of both institutional and retail investors.
For environmentally minded investors, the biotech industry has a low carbon footprint as most work is research-driven and not energy-intensive and as such, adding biotech exposure can help lower the average carbon footprint of a portfolio, Hannon said.
The biotech industry is highly regulated as measured by the S&P Biotechnology Select Industry Index and is free of any violators of the UN Global Compact (UNGC), which is a widely-followed benchmark of corporate good behaviour.
Hannon said alongside many other sectors, biotechs are striving towards ESG targets. Whilst a diversified biotech ETF such as its S&P Biotech ETF (ASX:CURE) is not explicitly tracking an ESG framework, Hannon noted many biotech companies within the fund focus on social good as their technology aims to aid people from all walks of life with disease treatments or even eradication.
Prescient Therapeutics (ASX:PTX)CEO and managing director Steven Yatomi-Clarke told Stockhead bringing life-changing therapies to patients is an incredibly challenging undertaking that requires resources and resilience.
PTX is at the forefront of game-changing personalised cancer treatments with a strong pipeline of promising therapies. The company has a growing list of collaborations with leading cancer organisations globally including Peter McCallum Cancer Centre, University of Texas MD Anderson Cancer Center, Yale, Oxford and UPenn.
Companies brave enough to take on this challenge call on investors to fund the research and development at least, until they become profitable, he said.
But at Prescient, when we accept a dollar from an investor, we are focussed on growing that into more than one dollar.
He said in the last two years, Prescient has spent around $8m of shareholder funds, but through consistent delivery of milestones and progress, the company has translated this $8m into over $100m of shareholder value.
So shareholders have enjoyed a handsome financial return, but additionally, they can be satisfied in knowing that their investment has resulted in incredibly exciting progress to create therapies that we believe are going to change lives.
AusBiotech is aiming to educate potential investors in life sciences companies about the unique ecosystem, through in-person events such as its AusBioInvest 2022 in Perth in October as well as plain English resources including The Guide to Life Sciences Investing
At Stockhead, we tell it like it is. While Prescient Therapeutics is a Stockhead advertiser, it did not sponsor this article.
Get the latest Stockhead news delivered free to your inbox.
"*" indicates required fields
It's free. Unsubscribe whenever you want.
You might be interested in
See the original post:
Biotechnology investing for the social good making money and a difference - Stockhead
SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.
Nautilus co-founder and CEO Sujal Patel is scheduled to participate in the following two executive panel discussions:
Interested parties may contact kristen.patrick@capitalone.com to register to attend the virtual event.
About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit http://www.nautilus.bio.
Media Contactpress@nautilus.bio
Investor Contactinvestorrelations@nautilus.bio
Go here to read the rest:
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit - GlobeNewswire
The U.S. Department of Health and Human Services (HHS) today announced actions the department will take following theExecutive Ordersigned September 12, 2022 by President Biden launching a National Biotechnology and Biomanufacturing Initiative (NBBI).
This initiative will help drive research and development, improve access to quality federal data, grow domestic manufacturing capacity, expand market opportunities for biobased products, train a diverse and skilled workforce, streamline regulatory processes for products of biotechnology, advance biosafety and biosecurity to reduce risk, protect the U.S. biotechnology ecosystem, and build a thriving and secure global bioeconomy with partners and allies.
In its implementation of the Executive Order, HHS intends to leverage biotechnology and biomanufacturing in order to achieve medical breakthroughs, reduce the overall burden of disease, and improve health outcomes. HHS will lead the U.S. government in strategically advancing biosafety and biosecurity innovation as part of a growing bioeconomy, to ensure biotechnology research and development and biomanufacturing infrastructure break new ground while reducing risk.
Building on the departments successes at bolstering the resilience of the domestic public health supply chain and on continued collaboration and partnership with the American private sector, HHS welcomes a whole-of-government approach to secure U.S. leadership and stewardship of an equitable, safe, and secure bioeconomy. The COVID-19 pandemic has highlighted the departments ability to foster innovative biotechnological treatments, diagnostics, and vaccines swiftly and safely as well as HHS ability to facilitate a more flexible regulatory environment in such circumstances.
With the launch of NBBI, HHS will:
More:
Fact Sheet - HHS.gov
Thank you very much to Jake and for the whole White House team here for the amazing work youve done to get us to this point.
At the Defense Department, this moment in the bioeconomy matters for a lot of reasons.
First, we know that biotechnology and biomanufacturing have transformative potential for our mission at DoD to defend the nation.
It helps us improve capabilities, solve logistics challenges in ways that are sustainable, to Secretary Granholms point, and to protect our people.
And of course we know that strategic competitors like China are themselves prioritizing these technologies. They want to displace U.S. leadership and they want to challenge our competitiveness.
Under Secretary Austins leadership at DoD, we know, though, that we have what it takes here in the U.S. to really footstomp what Jake said earlier we have here, the ability, the ingenuity, the resolve to lead the way, and we have the right kind of innovation ecosystem to make it happen.
So, what can DoD do to help in this space?
Well, over the next five years, DoD will be investing nearly $1.5 billion dollars to expand U.S. bioindustrial manufacturing infrastructure, strengthen biosecurity and cybersecurity at those facilities, and use biotechnology to bolster our supply chains.
The goal, really, is to help be a key catalyst for a domestic bioindustrial manufacturing base, and more quickly turn basic and applied research into operational prototypes and reliable, reproducible products that can be made at scale.
We believe these investments will incentivize biotech innovation and manufacturing capacity for products important both for commercial and defense supply chains, such as critical chemicals for lubricants, energetics, and fuels.
This investment really builds on a history of groundbreaking DoD investment in the biotech space.
You can think about DARPAs work 10 years ago that kickstarted a rapid-response mRNA vaccine platform for infectious diseases, or more recently funding that the department has provided for some of the early wastewater assessment work for COVID, which has great applications for force protection against the coronavirus or future pandemics and has offered spin-off potential for U.S. and overseas communities grappling with biothreats.
And I also understand I think we have here with us today two of DoDs nine Manufacturing Innovation Institutes, BioMADE and BioFabUSA, so thank you to them for all the great work theyre doing.
Going forward, we expect our focus on biotechnology and biomanufacturing to be transformative for what we do at DoD for our forces.
Let me just give you an example of some of the things that are already happening:
Those examples arent science fiction, I think as the folks in this room know. Like the institutions, companies and agencies represented here today, theyre proof of one of Americas greatest strategic assets and thats our incredibly-vibrant innovation ecosystem. Its the envy of the world, and we want to help keep it that way.
Thanks very much.
President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.
President Joe Biden on Monday invoked the national effort to land a man on the Moon 60 years ago in a speech touting his Cancer Moonshot initiative, which aims to slash cancer death rates across the United States by half.
The Democrat was in Boston for an address deliberately echoing John F. Kennedy's famous 1962 "Moonshot speech" in which he called for landing an American on the lunar surface -- something achieved in 1969, after his assassination.
This time, Biden is pushing government-backed efforts to coordinate and fund treatment of cancer, search for cures and generally to prevent the disease through better public health.
Cancer remains the number two cause of death after heart disease and Biden said his Cancer Moonshot can halve death rates over the next 25 years.
"I know we can do this together, because I know this: there's nothing, nothing, nothing beyond our capacity or ability if we work together as the United States of America," he said.
Biden said that as in 1962, when the country was in the thick of the Cold War and domestic tensions were high over civil rights, the United States today is at an "inflection point."
And like Kennedy with his Moon program, Biden said he wanted to set "a national purpose that could rally the American people in a common cause."
- Backing from JFK's daughter -
Caroline Kennedy, daughter of the assassinated JFK and now US ambassador to Australia, said her father had defied the doubters in the 1960s, when "scientists weren't sure even that a Moon landing on the surface of the Moon was possible."
Kennedy, however, "understood the power of the idea" and saw the project as a way to unite the country. "No one embodies that spirit more than President Joe Biden," she said. "As president, he has restored the soul of America."
The battle against cancer is personal for Biden: his son Beau died of brain cancer in 2015 when Biden was vice president to Barack Obama.
Biden noted that cancer "does not discriminate..., it doesn't care if you're a Republican or Democrat."
"I give you my word as a Biden: this Cancer Moonshot is one of the reasons why I ran for president."
The linkage to the Moon program also sought to add to Democratic momentum ahead of November's midterm congressional elections where the Democrats face the possibility of a Republican sweep in Congress, severely complicating the last two years of Biden's first term.
- Change the trajectory -
Biden said his plan will push for cures and ways to manage cancer, turning "more cancers from death sentences into chronic diseases that people can live with."
"We know we can change the trajectory," he said.
The president said he was harnessing funding but also government expertise in high-tech research similar to the defense industry, where public-private partnerships drive innovations in weaponry and other military needs.
A new agency named Advanced Research Projects Agency for Health (ARPA-H) and the White House's new "cancer cabinet" will "increase funding to break log jams and to speed breakthroughs," while getting entrepreneurs support from cutting edge scientists with NASA, the Pentagon and the energy department.
The goal is to "use all the assets we have," Biden said, and this "may require unusual partnerships."
- Biotech boost -
Earlier, Biden signed an executive order meant to bolster the trailblazing US biotech sector's efforts to take on growing commercial rivals in China.
The order brings federal support for "areas that will define US biotechnology leadership and our economic competitiveness in the coming decades," a senior Biden administration official told reporters.
The official said that while US biotech research leads the world, the industrial applications are increasingly in the hands of other countries.
"Unless we translate biotechnology innovation into economic and societal benefits for all Americans, other countries, including and especially China, are aggressively investing in this sector," posing a "risk," the official said.
The White House says the US biotech industry is on the cutting edge of medical advances -- recently seen in the rapid development of vaccines, tests and therapeutics to help manage the Covid-19 pandemic -- but that the potential scope goes much further.
The official speaking to reporters cited studies suggesting that "before the end of the decade, engineering biology holds the potential to be used in manufacturing industry that accounts for more than one third of global output. That's equivalent to almost $30 trillion in terms of value."
Growing areas for biotech industry include new plastics and rubbers, jet fuel, and environmentally friendly fertilizers.
Excerpt from:
Biotechnology to the fore as Biden evokes US Moon mission in renewed cancer fight - HT Tech
Scope of the Global Nano Biotechnology Market
Nano Biotechnology Market Report that covers exclusive and analytical data through the span of Ten years between 2022-2032. This report is exclusive and encompasses in-depth analysis and industry insights on Nano Biotechnology Market. What you will get by reading the report is not just charts, bars, and analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest of your organization.
The QMI research report published on the Global Nano Biotechnology Market is an in-depth study of market share, value, and dynamics and is an extensive study of market trends. In addition, geometric surveys are used for predictive analysis, PESTLE analysis, SWOT analysis, and real-time analytics. This is a recent research study, covering the current COVID-19 impact on the global market.
The Nano Biotechnology market report also offers leading players along with a comprehensive strategic scenario pertaining to market volume and market promotion. The report delivers an in-depth market with detailed research on revenue growth and profit study. Also, various graphs are clearly used to offer the data format for an accurate study of facts and figures. The rapidly shifting market scenario and primary & future evaluation of the influence are featured in the research study.
Click here to get a sample of the premium report: https://www.quincemarketinsights.com/request-sample-84960?utm_source=sk/dj
Competitive Landscape: Global Nano Biotechnology Market
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nano Bridging Molecules SA (Switzerland), XanTecBioanalytics GmbH (Germany), Nanobiotix (France) and Dabur Pharma (India)
A brief study of the major market players and manufacturers has been extensively offered in the report to address several queries of clients and readers. The study is targeted to help in the various business decisions and key investment priorities of major stakeholders with a brief analysis of suppliers, distributors, manufacturers, and traders.
Similarly, in this report, clients are rendered important cues on providers landscape and their current competition strength, which highly influence the development of the global Nano Biotechnology market. Further, leading providers, manufacturing landscape, percentage splits, market revenues, breakdowns of the product scenario, and growth details are studied through primary as well as secondary sources.
Understanding Segmentation: Global Nano Biotechnology Market
The Nano Biotechnology market has been segmented as By Application (Pharmaceuticals, Medical Devies, Medical Research, Food and Agriculture) By Therapeutics (Dental Therapies, Cardiac Therapies, Orthopedic Therapies, Others)
The global Nano Biotechnology market report also gives major data on the basis of comprehensive market segmentation. The global Nano Biotechnology Market segment chapter delivers the company total revenue (financials), sales and revenue generated, price, industry share, production sites and services, and product launches.
This report divides the market into various segments on the basis of type, application, technology, as well as geographical regions. Likewise, the report delivers other data such as product consumption, manufacturing details, production capacity, and supply and demand analysis of the market. For the period 2023-2032, this report delivers the Nano Biotechnology sales, revenue, and market share of this market.
Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-84960?utm_source=sk/dj
Regional Analysis of the Global Nano Biotechnology market
The market report delivers a major regional spectrum for market scope, and studies, and analyzes each geographical section of the market. The report also offers a detailed research on major insights such as import, consumption, export, supply, and demand. This research study offers regional analysis for regions such as Europe (Germany, France, United Kingdom, Russia, and Italy), North America (United States, Canada, and Mexico), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina), and Middle East & Africa (UAE, Egypt, Saudi Arabia, and South Africa).
The report provides insights on the following pointers:
Market Penetration: Detailed information on the product portfolio of the key market players in the Nano Biotechnology market.
Product Innovation/Development: Comprehensive insights into the upcoming technologies, research, and development activities as well as the product launches in the market.
Competitive Assessment: Assessment of the market strategies, business segments and geographical regions of the leading market players.
Market Development: Detailed information about the growing markets. The report also studies the market for various segments across the geographies.
Market Diversification: Comprehensive information about the new product launches, recent development, untapped geographies, and huge investment made by the market.
Quantitative data:
1. Market Revenue and Growth Rate by Type (Historical and Forecast)2. Market Revenue and Growth Rate by Application, such as Food, Beverages, Pharmaceuticals, Industrial & Chemicals, Cosmetics & Personal Care, Agriculture, Others.3. Market Revenue, Growth Rate, Volume, Type, and Application by Each Country (History and Forecast)4. Revenue, Volume, and YOY Growth Rate by Player (Base Year).
This report provides: 1) An overview of the global market for Nano Biotechnology market and related technologies.2) Analysis of global market trends, yearly estimates, and annual growth rate projections for compounds (CAGRs).3) Identification of new market opportunities and targeted consumer marketing strategies for the global Nano Biotechnology market.4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in the industry.
The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.
Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-84960?utm_source=sk/dj
Conclusion
The market overview details includes the extensively classified insights procured through several sources. This market report also follows significant market drivers, challenges, and threats that influence the growth of this market. It is a professional and a thorough study that focuses on primary and secondary drivers, market share, major segments, and regional analysis.
Significant market policies have also been studied from the techno-commercial scenario for getting better outcomes. This research study provides quantified data for current market scenario, along with offering an evaluation of the key market players and their growth strategies.
ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.
Contact:
Quince Market Insights
Pune, Maharashtra
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986
Email: [emailprotected]
Web: https://www.quincemarketinsights.com
Continued here:
Nano Biotechnology Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2032 - Digital Journal
Most of us are familiar with the propaganda aimed at glyphosate, the active ingredient in Roundup. For years, activists pushed fake news and disinformation about the seriously benign herbicide, mostly because it was associated with genetically modified crops. Francevowed to seriously curtail usewithin its borders. And now local governments around the U.S.,including New York City, are banning it entirely.
Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.
Consider Greenpeaces nonsensical opposition to genetically modified crops. The activist organizationhas promoted outright falsehoodsand lies about GMO crops online and in other formats for years. As a result some Southern African governments decided it was better to let their residents starvethan distribute GMO grainssent by other countries. And everyone knows thatGreenpeaces obstruction of Golden Rice [despite] a letter from 159 Nobel Laureatesbegging them to stop with the disinformation couldnt convince them.
Theres plenty of other examples, like GMO labeling, that I could point to. Unfortunately, were increasingly living in a post-truth world where most people only surround themselves with people they want to believe. And, if anything, its only getting worse. So while standing up to these coordinated attacks when they first develop on social media might not be fun and sexy, its more important than ever.
This is an excerpt. Read the original post here
View original post here:
Viewpoint: Here's how post-truth tactics became central to the anti-biotechnology playbook - Genetic Literacy Project
HARRISON, N.Y., Sept. 19, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer, announced today that preclinical data on ST101, the company's first-in-class peptide antagonist of C/EBP, were published online in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. The published data describe preclinical evidence to support the advancement of ST101 as a novel therapy for treating advanced solid tumors. The full manuscript titled "Anti-cancer activity of ST101, a novel antagonist of CCAAT/enhancer binding protein ", can be found online here.
The data in the manuscript detail ST101-antagonism of CCAAT/Enhancer Binding Protein (C/EBP), a basic leucine zipper family transcription factor that is upregulated or overactivated in many cancers, resulting in gene transactivation that drives oncogenesis. ST101 binds C/EBP, preventing its dimerization and enhancing ubiquitin-proteasome dependent C/EBP degradation. ST101 exposure significantly decreases expression of C/EBP target genes including genes responsible for survival, transcription factors and cell cycle-related proteins. The result of ST101 exposure is potent, tumor-specific in vitrocytotoxic activity in cancer cell lines including glioblastoma, breast, melanoma, prostate, and lung cancer, while normal human immune and epithelial cells are not impacted. In vivoxenograft models indicate that ST101 exposure results in potent tumor growth inhibition or regression,both as a single agent and in combination studies.
"The publication of ST101 in Molecular Cancer Therapeutics is an exciting achievement, highlighting the tremendous unmet need for novel therapies to treat solid tumor cancers and the role that ST101 can play to fill this need," said Jim Rotolo, Ph.D., Sapience's VP, Translational Pharmacology and Head of Research. "We are thrilled to publish the mechanism of action of ST101 and showcase the therapeutic promise of disrupting C/EBP-driven oncogenic activity. We look forward to reporting and publishing additional data on ST101 and advancing the program through its ongoing Phase 1-2 study."
In its ongoing Phase 1-2 study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM, a durable RECIST 1.1-confirmed partial response in a patient with cutaneous melanoma and long-lasting stable disease in several additional patients.
About ST101 and the Phase 1-2 StudyST101, a first-in-class antagonist of C/EBP, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). ST101-101 is an open-label, Phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 in patients with advanced solid tumors. The study consists of two phases: Phase 1 dose escalation/regimen exploration and Phase 2 dose expansion. In the ongoing Phase 2 dose expansion, Sapience is actively enrolling patients with GBM, metastatic cutaneous melanoma, castration-resistant prostate cancer and locally advanced or metastatic hormone-receptor positive breast cancer. In the ongoing dose escalation part of the study, ST101 has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients. In the ongoing Phase 2 dose expansion part of the study, ST101 has demonstrated clinical proof-of-concept with a mRANO-confirmed partial response in a patient with recurrent GBM and evidence of long-lasting stable disease in several additional patients.
ST101 has been granted Fast Track designation for recurrent GBM and advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy,as well as orphan designations from the FDA for advanced melanoma, glioma and AML, and from the European Commission for the treatment of glioma.
About Sapience TherapeuticsSapience Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Its pipeline of SPEARs (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. Sapience's lead program, ST101, is a first-in-class antagonist of C/EBP that has demonstrated clinical proof-of-concept in multiple indications. For more information on Sapience Therapeutics, please visitwww.sapiencetherapeutics.comand engage with us onLinkedIn.
Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.
ContactsSapience Therapeutics, Inc.Barry Kappel, Ph.D., M.B.A.President and Chief Executive Officer[emailprotected]
Media and Investor Contact:Amy ConradJuniper Point(858) 366-3243[emailprotected]
SOURCE Sapience Therapeutics
Read the original here:
Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide...
Biotechnology engineering is an undergraduate degree programme in applied sciences that amalgamates the facts from both Biological sciences and technology. This study utilizes the biological processes which include the study of microorganisms or knowledge of antibiotics and further implement them in various industrial purpose.
In simple terms, Biotechnology is a study which involves the use of living organisms. The living organisms are used to make useful chemicals which can be utilized in industries. Biotechnological products are used in areas like agriculture, food sciences and medicine.
Biotechnology engineers tend to work with a broad range of medical, technical and admin professionals. The key skillsets include:
The minimum eligibility criteria required in order to pursue a BTech programmein Biotechnology states that a candidate should have completed their + 2 education with PCB. While there are engineering institutes that consider Mathematics a compulsory subject in order to offer admissions to candidates, institutes like JNU does not make maths mandatory for seeking admissions into the BTech in Biotechnology programmes. Candidates who have studied Biology in +2 can also apply for admissions.
The syllabus and course curriculum for BTech in Biotechnology vary for each university. However, we have enlisted a general list of topics included in the course programmes.
Subjects
Topics
Objective
Inorganic chemistry
Chemical bonding
Acids and Bases
Catalysis
Polymers
Colloids
This course introduces the concepts of inorganic chemistry.
Foundation course in physics
Interference by the division of wavefront
Diffraction
Polarization
Introduction to lasers
Fibre optical
This course is designed to provide fundamental knowledge of theories and concepts in physics.
Life sciences
Origin of life
Histology
Nutrition
Energy utilization
This course focuses on the discipline of Life Sciences and concepts related to it.
Essential in mathematics
Algebra of matrices
Quadratic forms
Mean value theorems
Partial derivatives
Mathematics is an essential part of the core curriculum for engineering courses.
Concepts in biotechnology
Introduction to biotechnology
Protein structure and engineering
Plant cell culture
This course introduces to the discipline of biotechnology and explains some of the basic concepts of biotechnology.
Introduction to computers
Introduction
Data storage
Programming using C
In this course, students learn the basics of computer and programming languages.
Foundation course in organic chemistry
Electronic displacements
Reactive intermediaries
Stereochemistry
Organic Chemistry is an important subject in Biotechnology. This course explains the basic ideas in organic chemistry.
Life sciences
Coordination and control
Homeostasis
Asexual reproduction
This course intends to study Life Science in a broader horizon.
Electric sciences
Properties of conductor and insulators
Alternating currents
Measuring instruments
Transformers
This paper focuses on the basic concepts of electronics and electrical science.
Microbiology
Microbes in human life
Functional anatomy
Microbial growth
Microbiology is another important paper for Biotechnology. It introduces topics and concepts of microbiology.
Bioenergetics
Biochemical evolution
Carbohydrates
Nucleic acids
Lipids
This course focuses on the study of energy flow through living systems.
Cell biology
Cell
Nucleus
Cell signalling
Cell cycle and division
This course intends to study the structure and function of living cells.
Chemical engineering
Chemical equations
Hearts of solution
The flow of incompressible fluids
This course focuses on the basic concepts of chemical engineering.
Molecular biology
Structure and properties of nucleic acids
DNA replication
Gene mutation
This paper aims to study biological activity at the molecular level.
Enzyme technology
Introduction to enzymes
Specificity of enzymes
Immobilization of enzyme
Enzyme technology is a subfield of biotechnology. This course introduces the concepts and theories of this field.
Plant tissue culture
Cellular totipotency
Cell and suspension culture
Protoplast culture
Haploid culture
This course studies techniques used to maintain or grow plant cells, tissues or organs artificially in a lab.
Animal biotechnology
See original here:
Higher Education in India | Shiksha.com
On August 16, 2018, the NIH Director issued a statement describing a proposal to streamline the federal framework for oversight of gene therapy. This proposal, which was developed in conjunction with the Food and Drug Administration, included amending the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) to eliminate duplicative review and reporting requirements for human gene transfer protocols. The statement also describes NIHs effort to refocus the role of the NIH Recombinant DNA Advisory Committee (RAC) to be closer to its original mandate a transparent forum for science, safety, and ethics of emerging biotechnologies. After a 60-day public comment period, the NIH Guidelines have been updated to reflect these changes and the RAC has been renamed the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC).
The charter of the NExTRAC reflects the shift in focus of the committee while embracing the continuity of this important advisory committee.
Federal Register Notice
Charter of the NExTRAC
NIH Directors Statement
Under the Poliscope Blog
NIH Guide to Grants and Contracts Notice
HSINCHU, Sept. 11, 2022 /PRNewswire/ --Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines.
NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes.
"We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," said Sherif Bayoumy, the General Manager of Medtreq Medical Equipment.
The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technologyto make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level."
About Metreq Medical Equipment Bahrain
Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity.
About Brain Navi
Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.
SOURCE Brain Navi Biotechnology Co., Ltd.
View original post here:
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac...